Tesamorelin vs. Ipamorelin | The #1 A-Z Guide

tesamorelin review

Titus Thorne

Last Updated June 10, 2021

Are you curious about tesamorelin vs. ipamorelin and how these synthetic peptides stack up against each other?

Many researchers in the growth hormone therapy field are interested in the similarities and differences between tesamorelin and ipamorelin. Both of these peptides increase the synthesis and release of endogenous human growth hormone.

But they're slightly different from each other in how they work, as well as in their potential benefits and side effects. For example, tesamorelin is an FDA-approved treatment for reducing abdominal fat in HIV-infected patients with lipodystrophy, while ipamorelin has yet to complete human clinical trials and is typically administered in conjunction with a GHRH like tesamorelin or CJC-1295.

In this A-Z guide, we’ll detail these similarities and differences to help interested researchers decide which peptide merits their investigation.

Buy Tesamorelin from the #1 online Peptides vendor in the world: Peptides Sciences

Buy Ipamorelin from the #1 online Peptides vendor in the world: Peptides Sciences

P.S: This is not medical or legal advice. This is strictly for entertainment purposes. We are not doctors - nor lawyers. All information below is presented for use on "test subjects" only. Not for human consumption. Please read my disclaimer.


What are Research Peptides?

Research peptides, known as peptide drug products, are at the forefront of ongoing GH therapy research and experimentation [1]. They're essentially chains of molecules called amino acids — the same molecules that make up proteins. Peptides naturally occur in the body or can be synthesized in laboratory settings via chemical synthesis.

According to the United States Food & Drug Administration (FDA), any polymer composed of 40 or fewer amino acids can be considered to be a peptide. To date, there are over 100 peptide drug products marketed in the U.S., Europe and Japan — in a global market estimated to be worth over $20 billion [2].

Because peptide drug products are so promising, many scientists and researchers are eager to conduct further research. There are currently almost 500 peptides recognized by the FDA as having therapeutic value to potentially treat various diseases, including [3]:

  • Bone disorders
  • Genetic disorders
  • Cancer
  • Infectious disease
  • Cardiovascular problems
  • Immune system
  • Respiratory disorders
  • Eye disorders
  • Neurodegenerative problems
  • Poor hormonal health
  • Bone disorders

Some of the most commonly used GHRH-promoting peptide drug products include tesamorelin, ipamorelin and sermorelin.


tesamorelin


What is Tesamorelin?

Tesamorelin is a synthetic GHRH analogue that was created in the 1990s by the Canadian technology company Theratechnologies [4]. It has been approved by the FDA to treat visceral adiposity (excessive fat around the midsection) in HIV-infected patients with lipodystrophy [5]. For this purpose, it is sold under the trade name EGRIFTA.


Mechanism of Action

The chemical structure of tesamorelin is almost identical to the hypothalamic peptide “growth hormone-releasing hormone” (GHRH), which occurs naturally in the body. This hormone is part of the body's mechanisms to regulate the synthesis and release of human growth hormone (HGH).

Tesamorelin works by binding to receptors in the pituitary gland, and stimulating the gland to produce and release even more HGH. The result is an increase in the concentration of HGH in the blood [6]. By up-regulating the amount of HGH in the bloodstream, tesamorelin offers several research-backed benefits.


Benefits of Tesamorelin

Tesamorelin's main benefit is that it helps treat HIV-positive patients who suffer from lipodystrophy, a condition that leads to excessive visceral adipose tissue (VAT) around the trunk. Tesamorelin has been shown to decrease VAT and help decrease the waist circumference of adults with HIV [6].

In other clinical trials involving HIV-infected adults, tesamorelin has been shown to help decrease muscle fat while simultaneously increasing muscle area [7] and lowering levels of overall abdominal fat [8] caused by long-term antiretroviral therapy. Tesamorelin therapy has been shown to trigger lipolysis, or fat burning, especially around the abdominal area [9].
To date, the only tesamorelin research conducted on adults without HIV involved measuring levels of neurotransmitters in the brain. A Washington state study found that tesamorelin helps lower levels of myo-inositol (MI), an osmolyte linked to early-onset Alzheimer's disease [10].


Ipamorelin


What is Ipamorelin

Ipamorelin is a pentapeptide that was developed by Novo Nordisk, a Danish pharmaceutical company. Ipamorelin is composed of a chain of five amino acids, making it much simpler than tesamorelin. It is chemically very similar to the body's own natural growth hormone-releasing peptide (GHRP)-1, with the main difference being that it lacks the central dipeptide Ala-Trp found in GHRP-1 [11].

Unlike tesamorelin, ipamorelin has not been approved by the FDA for any use, and has yet to be reviewed in human clinical trials. All data related to ipamorelin's efficacy, benefits and safety is from animal studies.


Mechanisms of Action

Like tesamorelin, ipamorelin is a GH secretagogue, meaning that it promotes the synthesis and release of GH in vitro and in vivo. Animal studies have shown that ipamorelin is able to bind to primary rat pituitary cells and stimulate the release of GH into the blood. It binds to cells in the pituitary gland that prompts the release of additional HGH into the blood [11].

The other effect of ipamorelin is to suppress somatostatin. Somatostatin is a hormone that inhibits the production of HGH. By reducing this HGH inhibitor, ipamorelin indirectly increases the body's ability to produce additional HGH.


Benefits of Ipamorelin

Similar to tesamorelin, the main benefit of ipamorelin is that it appears to increase HGH levels. Based on the literature to date, composed of animal studies, we can conclude as follows:

  • The results of animal studies indicate that ipamorelin appears to be a “selective” GH secretagogue. This means it only up-regulates HGH, but not other hormones like cortisol or adrenocorticotropic hormone (ACTH) [11].
  • In a study involving young female rats, ipamorelin was shown to help increase “body weight gain” and enhance “in vitro basal and ipamorelin or GHRH-stimulated GH release” [12].
  • A study involving groups of 8-month-old female rats found that ipamorelin could “counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone” [13].
    Ipamorelin has been shown to induce longitudinal bone growth in rats [14].

Best Human Growth Hormone-Releasing Peptide

Great, so studies have shown that both tesamorelin and ipamorelin appear to offer similar benefits…but which one is better from a research standpoint?

While both peptides appear to increase the secretion and production of HGH in vitro and in vivo, only tesamorelin has undergone human clinical trials and has been approved by the FDA.

Another key difference between these two peptides is that ipamorelin does not adversely affect ACTH or cortisol, at least not based on the rat and swine studies [11].



Differences between Tesamorelin and Ipamorelin

Structure

The differences between ipamorelin vs. tesamorelin are primarily chemical.

They are both peptides, thus short chains of amino acids. But tesamorelin is much longer at 44 amino acids in length. By contrast, ipamorelin is made up of just five amino acids.

Mechanism of action

Their structural difference means that the two have a slightly different mechanism of action. Tesamorelin is a stabilized peptide analogue of growth hormone-releasing hormone (GHRH) while ipamorelin is a growth hormone-releasing secretagogue. They mimic slightly different chemicals in the body and bind to different receptors.

So while they have the same ultimate effect of increasing HGH, they do so in slightly different ways. Tesamorelin is an FDA-approved treatment for reducing excess abdominal fat in HIV-infected patients with lipodystrophy and can be taken on its own. Ipamorelin, on the other hand, has yet to pass human clinical trials and is typically taken in conjunction with tesamorelin or other

Ipamorelin vs. Tesamorelin Cost

Another key difference between ipamorelin and tesamorelin is the cost.

How much does ipamorelin cost? Ipamorelin costs about $50 for 5 mg, which is about 50 doses. $50 worth of ipamorelin can last the subject about 10 weeks — a bit less if their doses are larger.

Tesamorelin costs about $70 for 5 mg, which is about 5 doses. $70 of tesamorelin will last about 1 week — less with larger doses.

So ipamorelin costs significantly less than tesamorelin.


How Are Tesamorelin and Ipamorelin Dosed and Cycled?

This section will outline how tesamorelin and ipamorelin are typically dosed and cycled.

Tesamorelin Dosage and Administration

The recommended dose of tesamorelin (EGRIFTA™) for HIV-positive adult patients with lipodystrophy is 2 mg injected subcutaneously once daily [15].

Patients are typically instructed to follow this dosing schedule:

  • One subcutaneous injection containing 2 mg tesamorelin daily
  • Taken at the same time each day, ideally before bed
  • Five days per week
  • Continue for 60 days, with one month off

Ipamorelin Dosage and Administration

In terms of ipamorelin dosage, this peptide has not been approved for human use and therefore has no “recommended” dosage or cycling structure. Ipamorelin was investigated in phase II clinical trials for the treatment of postoperative ileus; however, these trials were discontinued due to lack of efficacy [16].

Participants in this small proof of concept study were given intravenous infusions of 0.03-mg/kg ipamorelin twice daily for 7 days after undergoing small and large bowel resection by open or laparoscopic surgery. The study found that “ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated” [16]. There is clearly potential for further research in terms of ipamorelin’s long-term safety and effects.

While anecdotal evidence suggests that many athletes and bodybuilders use tesamorelin and ipamorelin to improve body composition and athletic performance, there are no official or published figures to show at what dosage these peptides are taken [17].

However, recreational athletes who participated in a WADA-funded study into the effects of growth hormone on athletic performance were administered GH at a dose of 2 mg injected subcutaneously once daily [18]. This offers some indication of how GH is supplemented by athletes. Ipamorelin is typically administered at a lower dose in conjunction with a GHRH like tesamorelin or CJC-1295.


How to Order Research Peptides online

It's easy and perfectly legal to buy both tesamorelin and ipamorelin online for research purposes. But be careful: not every vendor is trustworthy. There are many vendors that sell low-purity peptides that don’t work, and can even be dangerous. Researchers interested in ordering peptides online should ensure that they source them from a reputable vendor.

How do you determine who is a trustworthy seller of tesamorelin vs. ipamorelin? Look for:

  • A website disclaimer making the terms and conditions of the product clear.
  • A site that publishes certificates of analysis that show 100% purity.
  • Independent reviews of the vendor from third-party websites.
  • Secure payment methods and a good guarantee.
  • Reasonable prices for both ipamorelin and tesamorelin.

In our opinion, the most reliable and consistent vendor to buy research peptides from online is Peptide Sciences. We've only had excellent experiences and we know that they offer extremely high-quality peptides.

The main benefits of Peptide Sciences include:

  • American-made peptides with publicly available certificates of analysis.
  • Convenient shipping options with very quick delivery.
  • Shipping to most countries in the world.
  • Secure payment options, including accepting cyber currencies like Bitcoin.
  • Great customer service with a strong product guarantee.

Side effects and Safety Concerns

So both tesamorelin and ipamorelin appear to be effective at promoting GH in the body. But are they safe? What are the side effects of ipamorelin and tesamorelin?

The short answer is that only tesamorelin has undergone human clinical trials and received FDA approval. Studies on ipamorelin in human subjects are lacking and this merits further research.

Here’s what we know.

Tesamorelin side effects

Tesamorelin has only been studied in HIV-positive adults. Results show that the most common side effects are:

  • Sweating
  • Redness, itching, pain, swelling, and irritation at the site of injection
  • Diarrhea
  • Muscle aches

Additionally, tesamorelin has been linked to glucose intolerance and found to increase the risk of type 2 diabetes mellitus. The drug is contraindicated during pregnancy [4].

Ipamorelin side effects

As ipamorelin has not been approved for human use, ipamorelin side effects require further research. As a GHRH secretagogue that is subcutaneously injected, it’s safe to assume that ipamorelin causes similar side effects related to frequent injections such as pain, rash or soreness at injection sites, in common with other forms of GH therapies [19].

Avoiding side effects

Researchers who are new to working with peptides are advised to start participants off with a low dose and give full instructions on how to self-administer these drugs to avoid injection-related complications.



Ipamorelin vs. Tesamorelin | Verdict

Between tesamorelin and ipamorelin, which ultimately wins out?

From an experimental standpoint, tesamorelin has the clear advantage of having been evaluated in human clinical trials and approved by the FDA for use in humans. It still presents many avenues for further research, such as long-term cardiovascular benefits and safety.

By comparison, ipamorelin has yet to receive FDA approval and remains a research peptide that is typically taken with a GHRH receptor agonist like tesamorelin itself or CJC-1295.

Buy tesamorelin and/or ipamorelin from our #1 recommended vendor…

Buy Tesamorelin from our #1 recommended vendor...


References

  1. Lee, Andy Chi-Lung et al. “A Comprehensive Review on Current Advances in Peptide Drug Development and Design.” International journal of molecular sciences vol. 20,10 2383. 14 May. 2019, doi:10.3390/ijms20102383
  2. Food and Drug Administration (2020). Impact Story: Developing the Tools to Evaluate Complex Drug Products: Peptides. Retrieved March 28, 2020. fda.gov
  3. THPdb: A database of FDA approved therapeutic peptides and proteins. Retrieved March 27, 2020. webs.iiitd.edu.in
  4. Patel, A., Gandhi, H., & Upaganlawar, A. (2011). Tesamorelin: A hope for ART-induced lipodystrophy. Journal of Pharmacy And Bioallied Sciences, 3(2), 319.
  5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Tesamorelin. 2018 Oct 20. PMID: 31644039.
  6. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. PMID: 222986
  7. Adrian, S., Scherzinger, A., Sanyal, A. et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 8, 154–159 (2019). https://doi.org/10.14283/jfa.2018.45
  8. Dhillon, S. Tesamorelin. Drugs 71, 1071–1091 (2011). https://doi.org/10.2165/11202240-000000000-00000
  9. Clinical Review Report: Tesamorelin (Egrifta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Executive Summary. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539124/
  10. Friedman SD, Baker LD, Borson S, et al. Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurol. 2013;70(7):883–890. doi:10.1001/jamaneurol.2013.1425
  11. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
  12. Jiménez-Reina, L., Cañete, R., De la Torre, M. J., & Bernal, G. (2002). Chronic in vivo Ipamorelin treatment stimulates body weight gain and growth hormone (GH) release in vitro in young female rats. European Journal of Anatomy, 6(1), 37-45.
  13. Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.
  14. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.
  15. (2021). Retrieved 29 May 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
  16. Beck, D.E., Sweeney, W.B., McCarter, M.D. et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 29, 1527–1534 (2014). https://doi.org/10.1007/s00384-014-2030-8
  17. Erotokritou-Mulligan, Ioulietta et al. “Growth hormone doping: a review.” Open access journal of sports medicine vol. 2 99-111. 27 Jul. 2011, doi:10.2147/OAJSM.S11626
  18. Meinhardt U, Nelson AE, Hansen JL, Birzniece V, Clifford D, Leung KC, Graham K, Ho KK. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med. 2010 May 4;152(9):568-77. doi: 10.7326/0003-4819-152-9-201005040-00007. PMID: 20439575.
  19. Souza, F. M., & Collett-Solberg, P. F. (2011). Adverse effects of growth hormone replacement therapy in children. Arquivos Brasileiros De Endocrinologia & Metabologia, 55(8), 559-565.

Table Of Contents